This trial will study the effects of a medication called treprostinil on people with pulmonary arterial hypertension. The goal is to see if the medication can lower the pressure in the arteries of the lungs and improve the function of the right ventricle of the heart.
- Pulmonary Arterial Hypertension
1 Primary · 13 Secondary · Reporting Duration: Baseline, Months 12, 24, and 36
1 Treatment Group
1 of 1
50 Total Participants · 1 Treatment Group
Primary Treatment: Treprostinil · No Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is recruitment for this clinical research still available?
"Correct. According to information available on clinicaltrials.gov, this medical study is actively recruiting for 50 patients from 2 sites as of October 27th 2022; the trial was initially posted 8/10/2022." - Anonymous Online Contributor
Has Treprostinil been green-lit by the FDA?
"There is sufficient clinical data to support treprostinil's safety, granting it a rating of 3." - Anonymous Online Contributor
How many participants are engaging in this research project?
"Affirmative. Clinicaltrials.gov discloses that the research study, which was posted on August 10th 2022 is still recruiting participants. 50 volunteers are needed for this trial between 2 selected medical facilities." - Anonymous Online Contributor